119 related articles for article (PubMed ID: 34130924)
1. Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.
Almansour H; Afat S; Serna-Higuita LM; Amaral T; Schraag A; Peisen F; Brendlin A; Seith F; Klumpp B; Eigentler TK; Othman AE
Acad Radiol; 2022 Apr; 29(4):514-522. PubMed ID: 34130924
[TBL] [Abstract][Full Text] [Related]
2. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy.
Schraag A; Klumpp B; Afat S; Gatidis S; Nikolaou K; Eigentler TK; Othman AE
Eur J Radiol; 2019 Dec; 121():108688. PubMed ID: 31704599
[TBL] [Abstract][Full Text] [Related]
3. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
4. Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Wang M; Chen C; Jemielita T; Anderson J; Li XN; Hu C; Kang SP; Ibrahim N; Ebbinghaus S
J Immunother Cancer; 2019 Feb; 7(1):39. PubMed ID: 30736858
[TBL] [Abstract][Full Text] [Related]
5. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
6. Quantified visual scoring of metastatic melanoma patient treatment response using computed tomography: improving on the current standard.
Gottlieb RH; Krupinski E; Chalasani P; Cranmer L
J Digit Imaging; 2012 Apr; 25(2):258-65. PubMed ID: 21785917
[TBL] [Abstract][Full Text] [Related]
7. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
[TBL] [Abstract][Full Text] [Related]
8. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
9. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
10. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
11. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
12. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
González Astorga B; Jiménez Rubiano B; Delgado Pérez JR; Valdivia Bautista J; Sánchez Toro C; González Flores E; Luque Caro R; Castellón Rubio V
Clin Transl Oncol; 2009 Jun; 11(6):382-6. PubMed ID: 19531453
[TBL] [Abstract][Full Text] [Related]
13. Interim [
Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
[TBL] [Abstract][Full Text] [Related]
14. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.
He L; Teng Y; Jin B; Zhao M; Yu P; Hu X; Zhang J; Li S; Gao Y; Liu Y
BMC Cancer; 2010 Dec; 10():681. PubMed ID: 21156055
[TBL] [Abstract][Full Text] [Related]
15. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
16. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.
Brouquet A; Abdalla EK; Kopetz S; Garrett CR; Overman MJ; Eng C; Andreou A; Loyer EM; Madoff DC; Curley SA; Vauthey JN
J Clin Oncol; 2011 Mar; 29(8):1083-90. PubMed ID: 21263087
[TBL] [Abstract][Full Text] [Related]
17. CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria.
Meyer M; Hohenberger P; Apfaltrer P; Henzler T; Dinter DJ; Schoenberg SO; Fink C
Eur J Radiol; 2013 Jun; 82(6):923-8. PubMed ID: 23410905
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.
Hayes SA; Pietanza MC; O'Driscoll D; Zheng J; Moskowitz CS; Kris MG; Ginsberg MS
Eur J Radiol; 2016 Mar; 85(3):524-33. PubMed ID: 26860663
[TBL] [Abstract][Full Text] [Related]
19. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
20. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
